Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Abstract Text:

Robert R McWilliams,Matthew P Goetz,Bruce W Morlan,Muhammad Salim,Kendrith M Rowland,James E Krook,Matthew M Ames,Charles Erlichman,

BACKGROUND: Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin. A combination regimen using all 4 agents could potentially increase response rates in CRC. PATIENTS AND METHODS: A multicenter phase II trial of oxaliplatin 85 mg/m(2) on day 1, irinotecan 175 mg/m(2) on day 1, 5-fluorouracil 240 mg/m(2) by 90-minute infusion on days 2-5, and leucovorin 20 mg/m(2) on days 2-5 of a 21-day cycle was undertaken in patients with CRC through the North Central Cancer Treatment Group. The primary endpoint was response rate, with secondary endpoints of toxicity and quality of life. RESULTS: Of 14 patients enrolled (13 evaluable), 3 partial responses were seen (23%; 95% confidence interval, 5%-54%), and 9 patients had stable disease (69%). Toxicity was significant, with 1 (8%) grade 5 event (diarrhea and dehydration) and 3 (23%) grade 4 events (leukopenia and diarrhea). The study was closed to further enrollment because of toxicity. CONCLUSION: The 4-drug regimen was extremely toxic. Future studies incorporating irinotecan- and oxaliplatin-based therapy should consider alternative schedules.

Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Publishing Authors By Initials

RR McWilliams,MP Goetz,BW Morlan,M Salim,KM Rowland,JE Krook,MM Ames,C Erlichman,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Clinical colorectal cancer

VOLUME: 6

Page Numbers: 516-21

Journal Abbreviation:

ISSN: 1533-0028

DAY: 3

MONTH: May

YEAR: 2007

Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101120693

Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: administration & dosage

Chemical & Substance for Abstract: Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Information

Substance Name: Camptothecin

Registry Number: 7689-03-4

Grant and Affiliation Information for Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.

AFFILIATION: Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA. mcwilliams.robert@mayo.edu

Country: United States

AGENCY: United States NCI

GRANT: CA37404

ACRONYM: CA

MEDLINETA: Clin Colorectal Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer Related Publications

• A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
• An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
• Cisplatin abrogates the geldanamycin-induced heat shock response.
• Dysphagia research in the 21st century and beyond: proceedings from Dysphagia Experts Meeting, August 21, 2001.
• HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
• P-glycoprotein-mediated resistance to hsp90-directed therapy is eclipsed by the heat shock response.
• Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
• Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.